LTR increases LevOmega stake to 43% with $1m investment
Filed with ASX · · 2 pages · English
Story so far
Earlier from LTR Pharma
- LTR Pharma secures 33% ownership in LevOmega Pty Ltd
- FY25 Results Announcement
- Appendix 4E and Annual Report to Shareholders
- SPONTAN Case Series - Strong Post-Prostatectomy Results
- 18-Month Shelf Life Strengthens SPONTAN Commercialisation
Later from LTR Pharma
- Ethics Approval Received for SPONTAN Phase II Clinical Study
- TGA Provides Regulatory Clearance for SPONTAN Phase II
- First Patients Dosed in SPONTAN Phase II Clinical Study
- Quarterly Activities/Appendix 4C Cash Flow Report
- SPONTAN Shows Positive Outcomes in Younger Men with ED
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma